The DOI matches its Crossref record; 144 of the 144 references it cites were found in a registry or an index.
Oxidative Damage in Huntington's Disease Pathogenesis
Abstract
Huntington's disease (HD) is a devastating neurodegenerative disorder characterized by the progressive development of involuntary choreiform movements, cognitive impairment, neuropsychiatric symptoms, and premature death. These phenotypes reflect neuronal dysfunction and ultimately death in selected brain regions, the striatum and cerebral cortex being principal targets. The genetic mutation responsible for the HD phenotype is known, and its protein product, mutant huntingtin (mhtt), identified. HD is one of several "triplet repeat" diseases, in which abnormal expansions in trinucleotide repeat domains lead to elongated polyglutamine stretches in the affected gene's protein product. Mutant htt-mediated toxicity in the brain disrupts a number of vital cellular processes in the course of disease progression, including energy metabolism, gene transcription, clathrin-dependent endocytosis, intraneuronal trafficking, and postsynaptic signaling, but the crucial initiation mechanism induced by mhtt is still unclear. A large body of evidence, however, supports an early and critical involvement of defects in mitochondrial function and CNS energy metabolism in the disease trigger. Thus, downstream death-effector mechanisms, including excitotoxicity, apoptosis, and oxidative damage, have been implicated in the mechanism of selective neuronal damage in HD. Here we review the current evidence supporting a role for oxidative damage in the etiology of neuronal damage and degeneration in HD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
The functional anatomy of basal ganglia disorders
Albin, R. L., Young, A. B., & Penney, J. B. (1989) · Trends in Neurosciences · doi:10.1016/0166-2236(89)90074-x · Cited by 5,353
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Neuropathological Classification of Huntingtonʼs Disease
VONSATTEL, J.-P., MYERS, R. H., STEVENS, T. J., FERRANTE, R. J., BIRD, E. D., & RICHARDSON, E. P. (1985) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-198511000-00003 · Cited by 2,227
Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death
Arrasate, M., Mitra, S., Schweitzer, E. S., Segal, M. R., & Finkbeiner, S. (2004) · Nature · doi:10.1038/nature02998 · Cited by 1,979
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595
Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase
Ischiropoulos, H., Zhu, L., Chen, J., Tsai, M., Martin, J. C., Smith, C. D., & Beckman, J. S. (1992) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(92)90431-u · Cited by 1,495
Ishii, T., Itoh, K., Takahashi, S., Sato, H., Yanagawa, T., Katoh, Y., Bannai, S., & Yamamoto, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.21.16023 · Cited by 1,460
G. Vonsattel, J. P., & DiFiglia, M. (1998) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199805000-00001 · Cited by 1,306
Cited by
Nitric oxide in the central nervous system: neuroprotection versus neurotoxicity
Calabrese, V., Mancuso, C., Calvani, M., Rizzarelli, E., Butterfield, D. A., & Giuffrida Stella, A. M. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2214 · Cited by 1,543
Oxidative Stress and Neurotoxicity
Sayre, L. M., Perry, G., & Smith, M. A. (2008) · Chemical Research in Toxicology · doi:10.1021/tx700210j · Cited by 867
Role of ROS and Nutritional Antioxidants in Human Diseases
Liu, Z., Ren, Z., Zhang, J., Chuang, C.-C., Kandaswamy, E., Zhou, T., & Zuo, L. (2018) · Frontiers in Physiology · doi:10.3389/fphys.2018.00477 · Cited by 860
Buendia, I., Michalska, P., Navarro, E., Gameiro, I., Egea, J., & León, R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.11.003 · Cited by 678
Apoptosis and Oxidative Stress in Neurodegenerative Diseases
Radi, E., Formichi, P., Battisti, C., & Federico, A. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132738 · Cited by 630
Basic mechanisms of neurodegeneration: a critical update
Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 596
The circadian clock and pathology of the ageing brain
Kondratova, A. A., & Kondratov, R. V. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3208 · Cited by 482
Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity
Rosas, H. D., Salat, D. H., Lee, S. Y., Zaleta, A. K., Pappu, V., Fischl, B., Greve, D., Hevelone, N., & Hersch, S. M. (2008) · Brain · doi:10.1093/brain/awn025 · Cited by 460
de Vries, H. E., Witte, M., Hondius, D., Rozemuller, A. J. M., Drukarch, B., Hoozemans, J., & van Horssen, J. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.09.001 · Cited by 428
Biological and physiological role of reactive oxygen species - the good, the bad and the ugly
Zuo, L., Zhou, T., Pannell, B. K., Ziegler, A. C., & Best, T. M. (2015) · Acta Physiologica · doi:10.1111/apha.12515 · Cited by 427
Deshmukh, P., Unni, S., Krishnappa, G., & Padmanabhan, B. (2017) · Biophysical Reviews · doi:10.1007/s12551-016-0244-4 · Cited by 398
Jiang, M., Wang, J., Fu, J., Du, L., Jeong, H., West, T., Xiang, L., Peng, Q., Hou, Z., Cai, H., et al. (2012) · Nature Medicine · doi:10.1038/nm.2558 · Cited by 345
Nrf2—a therapeutic target for the treatment of neurodegenerative diseases
Johnson, D. A., & Johnson, J. A. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.07.147 · Cited by 321
NRF2 as a Therapeutic Target in Neurodegenerative Diseases
Brandes, M. S., & Gray, N. E. (2020) · ASN Neuro · doi:10.1177/1759091419899782 · Cited by 297
Molecular Mechanisms and Potential Clinical Significance of S -Glutathionylation
Dalle–Donne, I., Milzani, A., Gagliano, N., Colombo, R., Giustarini, D., & Rossi, R. (2008) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1716 · Cited by 297
The Nrf2–ARE cytoprotective pathway in astrocytes
Vargas, M. R., & Johnson, J. A. (2009) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399409001094 · Cited by 291
Polyglutamine diseases: emerging concepts in pathogenesis and therapy
Shao, J., & Diamond, M. I. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm213 · Cited by 287
Mitochondria in Huntington's disease
Damiano, M., Galvan, L., Déglon, N., & Brouillet, E. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.012 · Cited by 284
Miller, B. R., Dorner, J. L., Shou, M., Sari, Y., Barton, S. J., Sengelaub, D. R., Kennedy, R. T., & Rebec, G. V. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.02.004 · Cited by 280
Recent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“The crucial initiation mechanism induced by mutant huntingtin (mhtt) is still unclear, but a large body of evidence supports an early and critical involvement of defects in mitochondrial function and CNS energy metabolism in the disease trigger (Browne and Beal 2006).”
BackgroundHeikkinen, T., Lehtimäki, K., Vartiainen, N., Puoliväli, J., Hendricks, S. J., Glaser, J. R., Bradaia, A., Wadel, K., Touller, C., Kontkanen, O., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050717 · Cited by 272
Catalase and glutathione peroxidase mimics
Day, B. J. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.09.029 · Cited by 269
Oxidative Stress and Huntington’s Disease: The Good, the Bad, and the Ugly
Kumar, A., & Ratan, R. R. (2016) · Journal of Huntington s Disease · doi:10.3233/jhd-160205 · Cited by 236
Mitochondrial Medicine for Aging and Neurodegenerative Diseases
Reddy, P. H. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8044-z · Cited by 230
“…in HD, several mechanisms have been proposed, including axonal trafficking, protein-protein interaction, transcriptional dysregulation, and mitochondrial oxidative damage (Browne and Beal 2004; Browne and Beal 2006; Li and Li 2006; Trushina et al. 2004; Trushina and McMurray 2007; Orr et al. 2008).”
BackgroundPerluigi, M., Coccia, R., & Butterfield, D. A. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4406 · Cited by 229
Mitochondria and Huntington's Disease Pathogenesis: Insight from Genetic and Chemical Models
Browne, S. E. (2008) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1427.018 · Cited by 176
The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies
Bauer, P. O., & Nukina, N. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06302.x · Cited by 178
Quinti, L., Dayalan Naidu, S., Träger, U., Chen, X., Kegel-Gleason, K., Llères, D., Connolly, C., Chopra, V., Low, C., Moniot, S., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1614943114 · Cited by 140
Dorrell, M. I., Aguilar, E., Jacobson, R., Yanes, O., Gariano, R., Heckenlively, J., Banin, E., Ramirez, G. A., Gasmi, M., Bird, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci35977 · Cited by 127
IRS2 increases mitochondrial dysfunction and oxidative stress in a mouse model of Huntington disease
Sadagurski, M., Cheng, Z., Rozzo, A., Palazzolo, I., Kelley, G. R., Dong, X., Krainc, D., & White, M. F. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46305 · Cited by 107
“org Volume 121 Number 10 October 2011 acteristic of HD, and oxidative damage was reported in early-stage HD progression in R6/2 mice, suggesting that mitochondrial dysfunction might promote neurodegeneration (9).”
InfluentialThe role of oxidative stress in Huntington’s disease: Are antioxidants good therapeutic candidates?
Gil-Mohapel, J., Brocardo, P., & Christie, B. (2014) · Current Drug Targets · doi:10.2174/1389450115666140115113734 · Cited by 101
Evidence for altered cholesterol metabolism in Huntington's disease post mortem brain tissue
Kreilaus, F., Spiro, A. S., McLean, C. A., Garner, B., & Jenner, A. M. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12286 · Cited by 92
Treating neurodegeneration by modifying mitochondria: potential solutions to a “complex” problem
Swerdlow, R. H. (2007) · Antioxidants & Redox Signaling · doi:10.1089/ars.2007.1676 · Cited by 81
Lloret, A., & Beal, M. F. (2019) · Neurochemical Research · doi:10.1007/s11064-019-02809-1 · Cited by 52
Self-citation
Metadata
- Authors
- Browne, S. E., & Beal, M. F.
- Venue
- Antioxidants & Redox Signaling
- Publisher
- SAGE Publications
- Published
- 2006-11
- Volume
- 8
- Issue
- 11-12
- Pages
- 2061-2073
- ISSN
- 1523-0864 (ISSN-L)
- 1557-7716
- OpenAlex
- W1978138384
- Cited by
- 310
- References
- 144
- FWCI
- 7.06
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.